EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lycium barbarum glycopeptide confers neuroprotection in chronic ocular hypertensive rats: a study investigating visual function, retinal structure, microcirculation, and pyroptosis

Chunlin Zhao, Wei Shi, Xuejing Lu

Frontiers in Pharmacology · 30.04.2026 · 17

DOI: 10.3389/fphar.2026.1829758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.04.2026. Verfasst von Chunlin Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eye School of Chengdu University of TCM, Chengdu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lycium barbarum glycopeptide (LbGp) has been reported to exert neuroprotective effects, yet its role in chronic ocular hypertension (COH) and the underlying mechanisms remain unclear. This study investigated whether LbGp protects against COH-induced retinal damage by inhibiting pyroptosis.

Methods

A COH rat model was established, and the animals were randomly assigned to model, LbGp, VX-765 (pyroptosis inhibitor), and VX-765+LbGp groups. After 28 days of treatment, visual function, retinal structure, microcirculation, and pyroptosis-related protein expression were assessed. In parallel, R28 cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) were used for in vitro validation.

Results

COH model rats exhibited marked visual dysfunction, retinal thinning, microvascular impairment, and upregulation of pyroptosis markers. LbGp treatment significantly attenuated these abnormalities and suppressed pyroptosis activation, showing efficacy comparable to that of VX-765. Notably, combined administration of LbGp and VX-765 produced synergistic effects. In vitro , LbGp similarly reduced pyroptosis-related protein expression in OGD/R-exposed R28 cells.

Conclusion

These findings demonstrate that LbGp confers neuroprotection against COH-induced optic nerve injury, at least in part, through inhibition of the pyroptosis pathway. This study provides experimental evidence supporting LbGp as a potential therapeutic candidate for glaucoma.

Schlagwörter

Stichwörter der Autor:innen

Lycium barbarum glycopeptidechronic ocular hypertensionmicrocirculationpyroptosisretinal structurevisual function

Autor:innen und Institutionen

  • Eye School of Chengdu University of TCM, Chengdu, China.
  • Sichuan Provincial Key Laboratory of Traditional Chinese Medicine for Ophthalmic Health, Chengdu, China.
  • Retinal Image Technology and Chronic Vascular Disease Prevention & Control and Collaborative Innovation Center, Chengdu, China.
  • Department of Ophthalmology, Hospital Affiliated of Nanjing University of Chinese Medicine, Nanjing, China.

Zitieren

APA

Zhao, C., Shi, W., & Lu, X. (2026). Lycium barbarum glycopeptide confers neuroprotection in chronic ocular hypertensive rats: a study investigating visual function, retinal structure, microcirculation, and pyroptosis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1829758

Vancouver

Zhao C, Shi W, Lu X. Lycium barbarum glycopeptide confers neuroprotection in chronic ocular hypertensive rats: a study investigating visual function, retinal structure, microcirculation, and pyroptosis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1829758

BibTeX
@article{Zhao2026,
  author = {Zhao, Chunlin and Shi, Wei and Lu, Xuejing},
  title = {Lycium barbarum glycopeptide confers neuroprotection in chronic ocular hypertensive rats: a study investigating visual function, retinal structure, microcirculation, and pyroptosis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1829758}
}
Kostenlos starten →